ISSN:
1433-2965
Keywords:
Bone mineral density
;
Monofluorophosphate
;
Osteopenia
;
Osteoporosis
;
Postmenopause
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract The aim of the present study was to assess the effects of the new fluorine pro-drug monofluorophos-phate (MFP) in postmenopausal women with vertebral osteopenia and high bone turnover. We enrolled postmenopausal women (PMW, 43–59 years) who had had a natural menopause 2–5 years before the study, had vertebral bone mineral density (BMD) 〈13 SD from the premenopausal mean, and had at least one of the biochemical markers of bone remodeling 〉1 SD over the mean for premenopausal women. Patients were randomly divided into two treatment groups (group 1, 500 mg/day of oral calcium; group 2, MFP at the dose of 20 mg F-equivalents + 600 mg calcium/day) for 2 years (n=21 in each group). The lumbar vertebral (L2–4) BMD and total body bone mineral (TBBM) were measured by dual-energy X-ray absorptiometry (Lunar DPX, Lunar Corporation, USA). Urinary hydroxyproline excretion (OH-P/Cr), plasma bone Gla protein (BGP) and serum alkaline phosphatase (AP) were assayed. In group 1 the markers of bone turnover and vertebral BMD did not show any significant modification, while TBBM showed a significant (p〈0.05) decrease after 24 months. In group 2 a significant (p〈0.05) decrease in OH-P/Cr (−23.9±2.0%), and an increase in both BGP (+19.4±2.6%) and AP(+10.3±2.6%) levels were observed after 24 months of MFP administration. In this group, both vertebral BMD (+5.01±0.9%,p〈0.01) and TBBM (+4.0±0.6%,p〈0.05) showed a significant increase after 24 months. Present results suggest that, in osteopenic PMW, MFP administration induces a significant increase in vertebral BMD without impairment of cortical bone, with a reduction in bone resorption and an increase in bone formation rate.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF01626610
Permalink
